title: The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia.
abstract: BACKGROUND
  The purpose of this study was to test the hypothesis that the addition of tandospirone, a 5-HT(1A) partial agonist, to ongoing treatment with typical antipsychotic drugs, would improve memory function in patients with schizophrenia.
  
  
  METHODS
  Eleven outpatients (male/female = 7/4) with schizophrenia who had been on stable doses of haloperidol and biperiden were given tandospirone, 30 mg/day, for 4 weeks. The Wechsler Memory Scale-Revised (WMS-R) was administered at baseline and 4 weeks after the addition of tandospirone. The Brief Psychiatric Rating Scale (BPRS; Total, Positive, and Negative subscale scores) and the Simpson-Angus Scale for Extrapyramidal Symptoms (SAS) were also completed on the two occasions. To exclude the possibility of a practice effect on the WMS-R test, 11 age-matched patients with schizophrenia (M/F = 7/4) were tested at baseline and after a 4-week interval.
  
  
  RESULTS
  Repeated measures analysis of variance revealed a significant time by group (patients with or without tandospirone) effect for the Verbal-, but not the Visual Memory composite scores of the WMS-R test; no significant change was observed in patients without tandospirone, whereas improvement in the Verbal Memory score was noted in patients receiving tandospirone. Moreover, there was improvement in the Inclusion score, an index of memory organization as measured by the Logical Memory subtest of WMS-R, only in patients with tandospirone. Scores on the BPRS and SAS were improved during treatment with tandospirone, but the effects did not reach statistical significance.
  
  
  CONCLUSIONS
  The results suggest that adjunctive treatment with 5-HT(1A) agonists may improve some types of memory function in schizophrenia.
authors.affiliation: Department of Neuropsychiatry, Toyama Medical and Pharmaceutical University, School of Medicine, Toyama, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sumiyoshi
authors.forename: M
authors.initials: M
authors.lastname: Matsui
authors.forename: I
authors.initials: I
authors.lastname: Yamashita
authors.forename: S
authors.initials: S
authors.lastname: Nohara
authors.forename: M
authors.initials: M
authors.lastname: Kurachi
authors.forename: T
authors.initials: T
authors.lastname: Uehara
authors.forename: S
authors.initials: S
authors.lastname: Sumiyoshi
authors.forename: C
authors.initials: C
authors.lastname: Sumiyoshi
authors.forename: H Y
authors.initials: HY
authors.lastname: Meltzer
mesh_terms: D000328:Adult; D001480:Basal Ganglia Diseases / Q000175:diagnosis; D010054:Brief Psychiatric Rating Scale; D003072:Cognition Disorders / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology* / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014705:Verbal Behavior; D014888:Wechsler Scales
chemical_list: D017366:Serotonin Receptor Agonists